CLINICAL UPDATES · SEASON 1 · EPISODE 9
Diabetic Kidney Disease: Slowing Progression
Diabetic kidney disease (DKD) is the leading cause of kidney failure worldwide, yet its early stages are silent and detectable only by screening. This Clinical Update reviews how DKD is found and staged, and the modern multi-pillar approach — glucose and blood pressure control plus kidney-protective drug classes — that has changed what progression looks like.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
MedicalVideos Clinical Updates is an educational series produced with full editorial independence. If an episode is sponsor-funded, that funding is labelled on the episode page and on the series hub.
The update
The clinical picture
Years of high blood glucose and pressure injure the kidney's filtering units. The earliest sign is albumin leaking into the urine — albuminuria — often while eGFR is still normal; later, filtration itself declines. DKD is staged using both measures together, because each predicts kidney and cardiovascular risk independently. Not every kidney problem in a person with diabetes is DKD: atypical features — rapid decline, active urinary sediment, or signs of another systemic disease — should trigger a search for a different cause, sometimes including biopsy. Cardiovascular disease, not kidney failure alone, is the biggest threat to most patients with DKD.
The current landscape
For decades the toolkit was glucose control, blood-pressure control, and renin–angiotensin system blockade. Outcome trials then added three further pillars. SGLT2 inhibitors, developed as glucose-lowering drugs, substantially slowed kidney decline and reduced heart-failure events in DKD trials. GLP-1 receptor agonists improved kidney outcomes in type 2 diabetes in dedicated trials. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduced progression and cardiovascular events on top of standard therapy. KDIGO's diabetes-in-CKD guideline organises these into layered, combined therapy — the era of single-drug management has ended, and the clinical challenge is now sequencing, tolerability, and access.
In practice
Screening is annual from diagnosis in type 2 diabetes and after the first years in type 1: a urine albumin-to-creatinine ratio plus eGFR, with abnormal results confirmed on repeat testing because albuminuria fluctuates. Blood-pressure treatment centres on renin–angiotensin blockade at tolerated doses, with potassium and creatinine checked after changes. Each added pillar is introduced with its own monitoring — potassium and kidney function for finerenone and RAS blockade, genital infection counselling for SGLT2 inhibitors. Sick-day guidance matters: patients learn which medicines to pause during dehydrating illness to protect the kidneys. Referral to nephrology is triggered by rapid progression, heavy albuminuria, diagnostic doubt, or advanced stage.
When to escalate
Escalate when eGFR falls rapidly, albuminuria is in the nephrotic range, or blood pressure resists control — each raises the possibility of a second, treatable kidney disease. A kidney biopsy is considered when the course is atypical for DKD. New foot ulcers, chest symptoms, or breathlessness in advanced DKD need prompt review because cardiovascular risk is high. Pregnancy in a patient with DKD requires early specialist co-management, since several kidney-protective medicines are not used in pregnancy.
Common questions
How is diabetic kidney disease diagnosed?
By persistent abnormalities on screening: albumin in the urine (albuminuria) and/or a reduced eGFR, present for more than three months in a person with diabetes, after other causes are considered. Both tests are simple — a urine sample and a blood test.
Can diabetic kidney disease be reversed?
Early albuminuria can improve substantially with glucose, blood-pressure, and kidney-protective treatment, and progression can be slowed dramatically. Established scarring does not fully reverse, which is why annual screening and early combination therapy matter so much.
What are SGLT2 inhibitors doing in kidney care?
These medicines block glucose and sodium reabsorption in the early tubule. Beyond lowering blood sugar, they reduce pressure inside the kidney's filters and protect the heart. Large trials in diabetic kidney disease showed slower progression to kidney failure, earning them a central place in guidelines.
If I have diabetes, how often should my kidneys be checked?
At least once a year with a urine albumin-to-creatinine ratio and a blood eGFR, and more often once abnormalities appear or medicines change. Ask for both tests — eGFR alone can miss early disease, because albuminuria often comes first.
More in Chronic Kidney Disease Care
Related
Related reading
Sources
- Diabetes Management in CKD Guideline (KDIGO)
- Diabetic Kidney Problems (MedlinePlus, US National Library of Medicine)
- Chronic Kidney Disease (CKD) (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK))
- CKD Evaluation and Management Guideline (KDIGO)
This Clinical Update is educational content for clinicians and informed patients. It is not medical advice and does not replace the judgment of the treating team. Drug classes are discussed in general terms only; prescribing decisions, doses, and monitoring belong with the patient's own clinicians. Drug eligibility in DKD depends on eGFR, potassium, and diabetes type; combinations are started and monitored by the treating team.